Scholarlink

Purpose of Review <p>Barrett’s esophagus (BE) is the only known precursor for esophageal adenocarcinoma. Patients diagnosed in endoscopy-based screening and surveillance programs have improved outcomes, but there are many limitations with current screening and surveillance paradigms. This review examines novel technologies aimed at improving current BE screening and surveillance strategies.</p> Recent Findings <p>BE risk stratification algorithms have decent discriminatory performance but are cumbersome to implement. Non-endoscopic screening tools, including swallowable cell collection devices, have shown good sensitivity and cost-effectiveness. Early studies of serum biomarkers, such as microRNA assays, have yielded promising results but warrant further validation. WATS-3D appears to increase dysplasia yield among patients undergoing surveillance. Tissue-based biomarkers may assist in risk stratification.</p> Summary <p>Novel, non-endoscopic technologies have the potential to enrich the BE screening population and improve outcomes, although most require further validation. Collaboration with primary care providers is critical to maximize the impact of such interventions. </p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A Practical Guide to Incorporating Novel Barrett’s Screening/Surveillance Tools into Clinical Practice

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月6日

查看全文
  • Brian E. White,
  • Alexandra L. Strauss Starling

摘要

Purpose of Review

Barrett’s esophagus (BE) is the only known precursor for esophageal adenocarcinoma. Patients diagnosed in endoscopy-based screening and surveillance programs have improved outcomes, but there are many limitations with current screening and surveillance paradigms. This review examines novel technologies aimed at improving current BE screening and surveillance strategies.

Recent Findings

BE risk stratification algorithms have decent discriminatory performance but are cumbersome to implement. Non-endoscopic screening tools, including swallowable cell collection devices, have shown good sensitivity and cost-effectiveness. Early studies of serum biomarkers, such as microRNA assays, have yielded promising results but warrant further validation. WATS-3D appears to increase dysplasia yield among patients undergoing surveillance. Tissue-based biomarkers may assist in risk stratification.

Summary

Novel, non-endoscopic technologies have the potential to enrich the BE screening population and improve outcomes, although most require further validation. Collaboration with primary care providers is critical to maximize the impact of such interventions.